Place your savings while boosting them on a large panel of UC and this in an advantageous tax framework.

Optimize your taxation, diversify your investments, prepare for your retirement with our wide range of products.

Place your savings while boosting them on a large panel of UC and this in an advantageous tax framework.

Optimize your taxation, diversify your investments, prepare for your retirement with our wide range of products.

Place your savings while boosting them on a large panel of UC and this in an advantageous tax framework.

Optimize your taxation, diversify your investments, prepare for your retirement with our wide range of products.

The “biotechs” monopolize the first places of the prize list this morning, and this in significant proportions! Quantum Genomics, Lysogen, Valneva, Ose Immuno, Gensight are particularly prominent! Some without any particular announcement.

For its part, the CAC40 is almost stable (0.05% to 6,685 points) in the first exchanges. Investors heard what they wanted to hear on Friday from Federal Reserve Chairman Jerome Powell, who did not give a specific timeline for the Federal Reserve’s stimulus cuts, either on the ‘tapering’ or rates, during his remarks at the Jackson Hole Symposium on Friday.

He said the Fed would remain cautious in any eventual rate hike decision as it tries to bring the economy back to full employment, saying it wants to avoid paying undue attention to inflation it still deems. ” transient “. In short, Powell has validated the ‘tapering’, without panicking the markets. Mission accomplished.

Many important statistics are expected during the week such as the publication of the ADP survey in the private sector (Wednesday) and that of the monthly report of the Department of Labor (Friday). Note that the London Stock Exchange is closed on Monday.

At the close of the market, the New York Stock Exchange ends well, supported by the intervention of Jerome Powell, the culmination of the virtual Jackson Hole symposium, the meeting of the world’s great money-makers. The exercise was expected and difficult, but the leader of the Fed got out of it, all in nuance and subtlety, leaving everyone free to interpret his speech.

The DJIA finished with a gain of 0.69% at 35,455 pts. The S&P 500 is firm, rising 0.88% to 4.509 pts. The Nasdaq Composite rose 1.23% to 15,129 pts for a new record at market close. The index of technology stocks also hit a new high in the session, at 15,144.48 points. The Nasdaq 100 takes 1.01%, ending at 15,432 pts.

The euro / dollar parity reached $ 1.1801 this morning. A barrel of Brent is trading at $ 73.47. An ounce of gold is traded at $ 1,813.

Quantum Genomics (15% at 5.93 Euros): listing resumed this morning for the title suspended on Friday. Quantum unveiled the results of firibastat in the QUORUM study, which, according to the group, paves the way for a new management of heart failure after myocardial infarction in severe patients. Among the main facts, Quantum mentions a comparable efficacy of firibastat and of the reference treatment (ramipril) in the entire population studied to prevent the degradation of the left ventricular ejection fraction (main endpoint) after myocardial infarction. It reports a more marked efficacy of firibastat compared to ramipril in severe patients with a low ejection fraction, as well as a greater improvement in the blood pressure profile under firibastat. Finally, the group mentions a good clinical tolerance of the two doses of firibastat.

Ose Immuno (5.34% to 12.22 Euros): continues after its jump of 14.17% Friday following the inclusion of the first patient of a phase 2 study in ovarian cancer. The phase 2 clinical trial evaluating Tedopi as monotherapy and in combination with Keytruda (pembrolizumab) from MSD, as a maintenance treatment in patients with relapsing ovarian cancer after failure of chemotherapy (Tedova study) .

Lysogen (8.74% at 2.42 Euros): announces the treatment of the first patient in the United States with the gene therapy drug candidate LYS-GM101, carried out at CHOC Hospital (CHOC) as part of the clinical trial Global Adaptive Design (NCT04273269) for the treatment of GM1 gangliosidosis. This trial is an interventional, multicenter, open-label, adaptive design two-phase study evaluating the intracisternal administration of a recombinant vector of adeno-associated virus serotype rh.10 (AAVrh.10).

Sanofi (-0.40% to 87.84 Euros): A pivotal phase III trial evaluating Dupixent (dupilumab) in children aged 6 months to 5 years with moderate to severe atopic dermatitis, a chronic disease with an inflammatory signature type 2, has met its primary endpoints and all of its secondary endpoints. The results of this trial show that at 16 weeks, the addition of Dupixent to corticosteroids for topical use (standard treatment) significantly reduces the overall severity of the disease and improves the healing of the skin, itching and health-related quality of life indicators compared to topical corticosteroid therapy only.

The information and advice written by the editorial staff of Boursier.com are produced from the best sources, even though Boursier.com cannot guarantee its completeness or reliability. These contents have no contractual value and in no way constitute an offer to sell or a solicitation to buy securities or financial instruments. The responsibility of the company Boursier.com and / or its managers and employees can not be engaged in the event of error, omission or inappropriate investment.

Or 120 € savings / year *
Offer Code: WIN21

For the first opening of a Bourse Direct account before August 31, 2021 inclusive,

Conditions of the Offer: Subscription to the Wincharts software offered during the life of the account benefiting from the offer, and subject to the service being maintained, for any first opening or transfer of an account with Bourse Direct between August 7, 2021 and August 31, 2021 inclusive. Offer reserved for new customers who have entered the offer code: WIN21 when opening an account online (https://www.boursedirect.fr/fr/bourse/ouvert-un-compte) or on their account opening file paper in the “Offer code” field and subject to receipt of a complete account opening file no later than August 31, 2021 (postmark as proof). Customers who already hold only a securities account with Bourse Direct will be able to benefit from the offer for the opening or transfer of a PEA or PEA-PME account; in the same way, clients who already hold only a PEA or PEA-PME account with Bourse Direct will be able to benefit from the offer for the opening or transfer of a securities account. Only one offer per person. Bourse Direct reserves the right to refuse to open an account at its discretion and to refuse or definitively exclude from participation in this operation any person who does not comply with the conditions of the offer. Bourse Direct reserves the right to discontinue the offer at any time subject to prior information on its website www.boursedirect.fr

LEVERAGE PRODUCTS PRESENTING A RISK OF CAPITAL LOSS DURING THE LIFE AND AT MATURITY.
Products intended for sophisticated investors with the necessary knowledge and experience
to assess the benefits and risks. See the “risk factors” section.

On the occasion of ESC 2021, Quantum Genomics presented the results of its phase IIb (QUORUM) study in heart failure …

Analog Devices (ADI) announced the completion of the previously published acquisition of Maxim Integrated Products. This merger strengthens ADI’s position as a semiconductor company …

Date: 8/30/2021
Underlying: STMicroelectronics
Product: Turbo Unlimited Best Call 1009T (ISIN: DE000UC2CM66).
Maturity: Open
Deactivating barrier: 27.3000
Strategy: Buy at 1.05…

According to “Les Echos, Engie is in exclusive negotiations with the Altrad companies with a view to the sale of Endel, its ailing industrial maintenance subsidiary. The energy company …

Opening your Bourse Direct account is free and is done online in a few minutes.
In the case of an account transfer, Bourse Direct takes care of
100% of your costs, up to € 200 per account.

Manage my cookies –
Personal data protection policy and cookies –
Security –
Legal Notice

2015 ® Bourse Direct – All rights reserved – SSL secured site

Related title :
Quantum Genomics s& # 39; takes off on the stock market when it resumes trading
Quantum Genomics: Oddo reduces its target
Opening in Paris: stable CAC40, biotechs in sight!
CM – Quantum Genomics rating is again significantly higher after positive results from …
Quantum Genomics’ listing resumes sharply higher after positive firibastat results

Ref: https://www.boursedirect.fr